Gedeon Richter upgrades 2026 guidance on strong delivery

Gedeon Richter Plc. has raised its full-year revenue and profit guidance for 2026, following a strong performance in the first nine months of the year. The Hungarian pharmaceutical company reported an 11.7% increase in pharma revenues at constant exchange rates during the period, reaching HUF 686.5bn. While currency fluctuations negatively impacted the results by approximately 9 percentage points, the company's BIO division is nearing breakeven, and continued strength in cariprazine contributed to the growth. Operating expenses have also been reduced through efficiency initiatives.

Clean EBIT, adjusted for constant exchange rates, grew by 25% in the nine-month period, reaching HUF 229.9bn. Reported Clean EBIT increased by 8% to the same figure. The company's net profit attributable to owners reached HUF 174.9bn in the nine-month period, up 7.1% compared to the previous year. Free cash flow before mergers and acquisitions increased by 12% to a record HUF 223bn.

Gedeon Richter's CNS segment revenues grew by 19% at constant exchange rates, driven by the strong sales of Vraylar, which reached $3.04bn at AbbVie, a 17% increase from the previous year. Reagila sales jumped by 37% at constant exchange rates. Women's Healthcare sales grew by 11% at constant exchange rates, with the growth accelerating to 19% in the third quarter.

The main contributors to revenue growth were Ryeqo, Lenzetto, and Drovelis. BIO revenues increased by 35% at constant exchange rates, supported by biosimilar products and contract development and manufacturing organization (CDMO) revenues.